Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 31 Glioblastoma 28 Breast Neoplasms 20 Lung Neoplasms 17 Carcinoma, Non-Small-Cell Lung 16 Oropharyngeal Neoplasms 14 Squamous Cell Carcinoma of Head and Neck 11 Sarcoma 10 Esophageal Neoplasms 10 Urinary Bladder Neoplasms 9 Gliosarcoma 9 Glioma 9 Astrocytoma 9 Brain Neoplasms 8 Triple Negative Breast Neoplasms 7 Neoplasm Metastasis 7 Mouth Neoplasms 7 Uterine Cervical Neoplasms 6 Rectal Neoplasms 6 Melanoma 6 Head and Neck Neoplasms 6 Carcinoma, Hepatocellular 6 Carcinoma 6 Adenocarcinoma Of Esophagus 6 Stomach Neoplasms 5 Pancreatic Neoplasms 5 Neoplasms 5 Laryngeal Neoplasms 5 Carcinoma, Squamous Cell 5 Burkitt Lymphoma 5

Interventions

Cyclophosphamide 49 fludarabine 36 Dexamethasone 35 venetoclax 29 pembrolizumab 26 Rituximab 21 Lenalidomide 18 pomalidomide 17 Gemcitabine 17 fludarabine phosphate 15 Etoposide 14 Cytarabine 13 daratumumab 11 carfilzomib 11 Temozolomide 11 Cisplatin 10 Calcium Dobesilate 10 glofitamab 9 Nivolumab 9 Injections 9 Azacitidine 9 selinexor 8 Vincristine 8 Carboplatin 8 Bortezomib 8 obinutuzumab 7 Immunotherapy, Adoptive 7 Bevacizumab 7 zanubrutinib 6 ruxolitinib 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Radiation × 1 year × Clear all

NCT03970447 2026-05-15

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡